金融界4月18日消息,有投资者在互动平台向恩华药业提问:请问下贵公司的地佐辛注射液上市了吗?现在处于离上市什么阶段?地佐辛在国外退市了,贵公司认为地佐辛的临床价值如何?是否存在过度滥用的可能?
公司回答表示:公司在积极配合审核部门(CDE)对公司报产的地佐辛注射液的审批工作,目前处于综合审评阶段,力争早日获批上市。该产品在国内的应用尚有空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.